Navigation Links
Regeneron Named Top Employer in the Global Biopharmaceutical Industry for the Second Year in a Row
Date:10/24/2013

TARRYTOWN, N.Y., Oct. 24, 2013 /PRNewswire/ -- Regeneron Pharmaceuticals, Inc. (Nasdaq: REGN) today announced that Science magazine has ranked Regeneron as the #1 employer in the global biopharmaceutical industry in the journal's annual Top Employers Survey for the second year in a row.  This distinction will be celebrated Monday, October 28, in conjunction with a groundbreaking ceremony for two new buildings to be constructed at the Regeneron campus in Westchester County, New York.

U.S. Senator Charles E. Schumer, U.S. Rep. Nita Lowey, Empire State Development Corp. President & CEO Kenneth Adams, and other public officials are scheduled to participate in an event with Regeneron employees that will celebrate the biotechnology company's latest expansion and the emergence of the lower Hudson Valley as a life sciences cluster.

"Regeneron's tremendous growth and our current expansion plans are undoubtedly thanks to our employees.  If we are the best place to work, it is because we have the best employees and a culture where they feel empowered and challenged," said Leonard S. Schleifer, M.D., Ph.D., President and Chief Executive Officer of Regeneron.
George D. Yancopoulos, Chief Scientific Officer and President, Regeneron Laboratories, said,  "As we are a company founded on scientific excellence, it is very meaningful to us to be recognized by Science magazine two consecutive years now as the top place to work in the industry." 

The new facilities, for which site preparation is underway, will include a total of 300,000 square feet of laboratory and office space, with a projected move-in date of third quarter 2015.  The expansion will increase Regeneron's square footage on the campus by more than 40 percent and make it possible for Regeneron to create approximately 400 new full-time jobs in Westchester, where it currently employs more than 1,500.  With a total of over 2,200 employees, including nearly 700 in the Regeneron Industrial Operations and Product Supply group in Rensselaer, New York near Albany, Regeneron is the largest biotechnology company in New York State and one of the five largest in the world by market capitalization.

The 2013 Science survey sought to identify the companies with the best reputations as employers, based on 3,656 survey responses from readers of Science and other survey invitees.  Survey participants came from North America (81%), Europe (10%), and Asia/Pacific Rim (7%); over 80% worked in private industry.  Details of the rankings and survey results can be found in sciencecareers.org and will be featured in the October 25, 2013 print issue. 

About Regeneron Pharmaceuticals
Regeneron is a leading science-based biopharmaceutical company based in Tarrytown, New York that discovers, invents, develops, manufactures, and commercializes medicines for the treatment of serious medical conditions.  Regeneron markets medicines for eye diseases, colorectal cancer, and a rare inflammatory condition and has product candidates in development in other areas of high unmet medical need, including hypercholesterolemia, oncology, rheumatoid arthritis, asthma, and atopic dermatitis.  For additional information about the company, please visit www.regeneron.com.Contact Information:Manisha Narasimhan, Ph.D.Peter DworkinInvestor RelationsCorporate Communications914.847.512914.847.764manisha.narasimhan@regeneron.competer.dworkin@regeneron.com


'/>"/>
SOURCE Regeneron Pharmaceuticals, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related biology technology :

1. Regeneron Announces Presentation at the Leerink Swann 2012 Global Healthcare Conference
2. Regeneron Announces March 2012 Investor Conference Presentations
3. Sanofi and Regeneron Announce Publication of Positive Phase 2 Results for Lipid-Lowering PCSK9 Antibody in The Lancet
4. Sanofi and Regeneron Launch Comprehensive Phase 3 Clinical Program With LDL Cholesterol-Lowering PCSK9 Antibody
5. Regeneron Pharmaceuticals’ Industrial Operations & Product Supply Site Receives International Recognition for Operational Excellence
6. Regeneron Reports First Quarter 2013 Financial and Operating Results
7. Zacks Investment Ideas feature highlights: Market Vectors Biotech ETF, iShares Nasdaq Biotechnology ETF, Regeneron, Celgene and First Trust Amex Biotechnology Index Fund
8. After 18 Months On the U.S. Market, Regenerons Eylea Captures One-Fifth of First-Line Intravitreal Pharmacotherapy Share Among Wet Age-Related Macular Degeneration (AMD) Patients
9. Callibra, Inc. dba Discharge 1-2-3 is Named Winner of 2011 Chicago Innovation Award
10. Dr. Alice Jacobs, CEO of IntelligentMDx, Named Best Entrepreneur in Eighth Annual Stevie® Awards for Women in Business
11. Sequenom Named to NASDAQ Global Select Market
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/4/2016)... ... February 04, 2016 , ... Franz Inc. ... Graph Database technology has been recognized As “ Best in Semantic Web Technology ... , “At Corporate America, it’s our priority to showcase prominent professionals who are ...
(Date:2/3/2016)... 2016   ViaCyte, Inc ., a leading, ... stem cell-derived islet replacement therapy for the treatment ... announced that ViaCyte and Janssen Biotech, Inc., one ... Johnson, have agreed to consolidate the assets of ... provides ViaCyte with an exclusive license to all ...
(Date:2/3/2016)... COPENHAGEN, Denmark , Feb. 3, 2016 ... stage biotechnology company that applies its innovative TransCon technology ... to present at an upcoming investor conference.Event:2016 Leerink Partners ... York, NY Date:  , Wednesday, February 10, 2016 Time:  ... --> www.ascendispharma.com . --> An audio ...
(Date:2/3/2016)... Denver, Colorado (PRWEB) , ... February 03, 2016 ... ... to hospitals, has established a new office dedicated to the North American healthcare ... provide turnkey solutions to healthcare facilities. The company will provide new pneumatic ...
Breaking Biology Technology:
(Date:2/1/2016)... -- Today, the first day of American Heart Month, the ... first of its kind workplace health solution that leverages ... first application of Watson to ... Welltok will create a new offering that combines AHA,s ... on Welltok,s health optimization platform. The effort is intended ...
(Date:1/25/2016)... , Jan. 25, 2016   Unisys Corporation (NYSE: ... John F. Kennedy (JFK) International Airport, New York City ... (CBP) identify imposters attempting to enter the United States ... to them. pilot testing of the system at ... three terminals at JFK during January 2016. --> pilot ...
(Date:1/21/2016)... , January 21, 2016 ... to a new market research report "Emotion Detection and ... Others), Software Tools (Facial Expression, Voice Recognition and ... - Global forecast to 2020", published by MarketsandMarkets, ... expected to reach USD 22.65 Billion by 2020, ...
Breaking Biology News(10 mins):